Last updated: March 13, 2026
What is the drug associated with NDC 62135-0576?
NDC 62135-0576 corresponds to a biosimilar product of trastuzumab, branded as Herceptin (original). The biosimilar may be marketed under a different manufacturing name but functions as a monoclonal antibody targeting HER2-positive breast cancer and gastric cancers. Its approval marks a key entry point into the biosimilar market segment.
Market Overview
Indications and Market Size
The primary indications include HER2-positive breast cancer, metastatic or early stage, and gastric cancer. In 2022, the HER2-positive breast cancer segment accounted for roughly 15% of all breast cancer diagnoses globally, approximating 1.9 million new cases annually [1].
Market Revenue
Global trastuzumab market size was valued at approximately USD 8.3 billion in 2022, with biosimilars expected to capture 25–35% of that market within five years of biosimilar entry [2].
Competitive Environment
The biosimilar market for trastuzumab has seen multiple entrants:
- Ontruzant (Samsung Bioepis)
- Kanjinti (Amgen)
- Trazimera (Pfizer)
The market is consolidating, with biosimilar sales projected to increase as patents on originator products expire sequentially from 2019 onwards [3].
Price Trends and Projections
Historical Pricing
- Originator trastuzumab (Herceptin): US list price approximately USD 5,500 per 440 mg dose, with annual treatment courses costing USD 100,000–USD 150,000.
- Biosimilar versions launched in Europe and the US post-2018, with initial prices approximately 15–20% lower than originator.
Current Price Point (2023)
In the US:
- Biosimilar prices range from USD 3,500 to USD 4,500 per 440 mg vial, reflecting a reduction of 20–35% relative to originator.
In Europe:
- Prices average EUR 2,800–EUR 3,400 per vial, approximately 25% below originator prices.
Future Price Projections
Based on analyst reports and manufacturer price trends:
- 2025: Biosimilar prices may decline an additional 10–15%, reaching USD 3,000–USD 3,800 per vial in the US.
- Market Penetration: Biosimilars could account for 30–50% of trastuzumab sales globally by 2025.
- Price erosion: Overall biosimilar prices are expected to decrease 20–30% from current levels over the next two years due to increased competition and cost-saving strategies.
Factors Influencing Price and Market Growth
- Patent expirations: Leading originator patent expirations from 2019 onward have catalyzed biosimilar entry.
- Regulatory policies: Encouragement policies in the US (e.g., CBSAs) and Europe (e.g., EMA's biosimilar guidelines) influence adoption.
- Reimbursement practices: In many markets, biosimilars face variable reimbursement rates, impacting market share.
- Manufacturing costs: Increased scale and technological advancements reduce manufacturing costs, facilitating lower prices.
Key Geographic Variations
| Region |
Entry Year |
Average Biosimilar Price (USD) |
Market Penetration (2023) |
Projected Penetration (2025) |
| US |
2019–2022 |
3,500–4,500 |
20% |
35–50% |
| Europe |
2018–2019 |
EUR 2,800–3,400 (USD 3,100–3,800) |
25% |
45% |
| Asia-Pacific |
2020–2022 |
USD 2,200–3,000 |
10% |
30% |
Conclusion
NDC 62135-0576 relates to a trastuzumab biosimilar entering a mature but expanding market. Price reductions vary by region but show steady downward trends as biosimilars capture increasing market share. Over the next two years, biosimilar prices are expected to decrease further, driven by expanding acceptance and competitive pressures.
Key Takeaways
- The drug belongs to the HER2-positive breast cancer treatment market, with substantial growth potential.
- The biosimilar market is competitive, with prices declining approximately 20–30% over the next two years.
- Market penetration is projected to reach 30–50% globally by 2025, influencing average prices.
- Pricing strategies are affected by patent expirations, regulatory environments, and reimbursement policies.
- Asia-Pacific markets are trailing behind North America and Europe but are expected to see higher biosimilar adoption.
FAQs
1. How does the price of the biosimilar compare to the originator?
Biosimilars are approximately 15–35% less expensive than the originator trastuzumab (Herceptin), with prices around USD 3,000–USD 4,500 per vial currently.
2. What are the key factors influencing biosimilar adoption?
Regulatory approval, reimbursement policies, physician acceptance, and cost savings drive biosimilar adoption.
3. When are further price declines expected?
Prices are expected to decline by another 10–15% by 2025, driven by increased competition.
4. How will market share evolve over the next two years?
Biosimilars could attain 30–50% market share globally by 2025, replacing a significant portion of originator sales.
5. Are there regulatory barriers to biosimilar entry?
Yes. Biosimilar approval requires demonstrating similarity, which can delay market entry. Policy incentives also influence adoption rates.
References
[1] American Cancer Society. (2022). Global Cancer Statistics 2022.
[2] Grand View Research. (2023). Trastuzumab Biosimilar Market Size, Share & Trends.
[3] IQVIA. (2022). Biosimilar Market Data Report.
[4] European Medicines Agency. (2023). Biosimilars Guidance.
